GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: Sepsis vs burns

Your views are similar to mine. I had previously expected burns to be the acquired-deficiency indication selected by Leo and GTC; the harbinger that the decision might go the other way was the recent attention by various parties to revisiting the KyberSept data. Rarely have I seen so many articles in the peer-reviewed literature about reanalyzing data from a 5-year-old study.

I think the fact that sepsis is an approved indication for plasma AT in Japan was significant factor too.